



Dr.Reddy's 

GASTRONOMY 4.0



14 **OCT**
2022
FRIDAY



5:00 PM
-
9:00 PM



Program Director

Dr. Senthil Rajappa

Sr. Consultant Medical Oncologist,
Basavatarakam Indo American
Cancer Hospital & Research Institute,
Hyderabad



Program Co-ordinator

Dr. Viraj Lavingia

Consultant Medical Oncologist,
HCG Cancer Hospital,
Ahmedabad

For the use of a Registered Medical Practitioner, Hospital or Laboratory only.

By accepting this invite to the event, you hereby agree to the T&C at <https://www.drreddys.com/privacy-notice.aspx> in respect of the handling of your personal data by Dr. Reddy's. Your participation at the event shall not be construed to: (a) require you to promote, purchase, prescribe, or otherwise recommend any Company products or services; or (b) interfere with your clinical decision-making.

The opinions expressed in the presentation are solely the views of the speaker.



Join virtually

Click link below for Registration
<https://riverroute.in/gastronomy>

Virtual Meeting Managed by
riverroute
Leaders in Streaming Modules

GASTRONOMY 4.0

Scientific Program

UPPER GI CANCERS | Time 05:00 PM to 6:00 PM

05:00 PM - 05:05 PM	<p>FOLFOX plus nivolumab and ipilimumab versus FOLFOX induction followed by nivolumab and ipilimumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: Results from the randomized phase II Moonlight trial of the AIO</p> <p>Speaker: Dr. Bhavesh Poladia</p>
05:05 PM - 05:10 PM	<p>Updated analysis of DESTINY-Gastric02: A phase II single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients (Pts) with HER2-positive (HER2+) unresectable/metastatic gastric/gastroesophageal junction (GEJ) cancer who progressed on or after trastuzumab-containing regimen</p> <p>Speaker: Dr. Palanki Satya Dattatreya</p>
05:10 PM - 05:15 PM	<p>Surgical and pathological outcome, and pathological regression, in patients receiving perioperative atezolizumab in combination with FLOT chemotherapy versus FLOT alone for resectable esophagogastric adenocarcinoma: Interim results from DANTE, a randomized, multicenter, phase IIb trial of the FLOT-AIO German Gastric Cancer Group and Swiss SAKK</p> <p>Speaker: Dr. Arun Chandrasekharan</p>

For the use of a Registered Medical Practitioner, Hospital or Laboratory only.

By accepting this invite to the event, you hereby agree to the T&C at <https://www.drreddys.com/privacy-notice.aspx> in respect of the handling of your personal data by Dr. Reddy's. Your participation at the event shall not be construed to: (a) require you to promote, purchase, prescribe, or otherwise recommend any Company products or services; or (b) interfere with your clinical decision-making.

The opinions expressed in the presentation are solely the views of the speaker.

GASTRONOMY 4.0

Scientific Program

UPPER GI CANCERS | Time 5:00 PM to 6:00 PM

05:15 PM - 05:20 PM

Nimotuzumab plus concurrent chemo-radiotherapy versus chemo-radiotherapy in unresectable locally advanced esophageal squamous cell carcinoma (ESCC): Interim analysis from a prospective, randomized-controlled, double-blinded, multicenter, and phase III clinical trial (NXCEL1311 Study)

Speaker: Dr. Rakesh Reddy B

05:20 PM - 06:00 PM

PANEL DISCUSSION

Moderator: Dr. M Vamshi Krishna

Panelists: Dr. Prasad Narayanan
Dr. Harish Peshwe
Dr. Boman Dhabhar
Dr. Rajat Saha
Dr. Shrikant Tiwari
Dr. E Prasad
Dr. Naresh Jadhav

HCC | Time 6:00 PM to 7:00 PM

06:00 PM - 06:05 PM

Final analysis of RATIONALE-301: Randomized, phase III study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma

Speaker: Dr. Akash Tiwari

06:05 PM - 06:10 PM

Primary results from the phase III LEAP-002 study: Lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC)

Speaker: Dr. Javvid Muzamil

For the use of a Registered Medical Practitioner, Hospital or Laboratory only.

By accepting this invite to the event, you hereby agree to the T&C at <https://www.drreddys.com/privacy-notice.aspx> in respect of the handling of your personal data by Dr. Reddy's. Your participation at the event shall not be construed to: (a) require you to promote, purchase, prescribe, or otherwise recommend any Company products or services; or (b) interfere with your clinical decision-making.

The opinions expressed in the presentation are solely the views of the speaker.

Click link below for Registration
<https://riverroute.in/gastronomy>

Virtual Meeting Managed by
riverroute
Leaders in Streaming Modules

GASTRONOMY 4.0

Scientific Program

HCC | Time 6:00 PM to 7:00 PM

06:10 PM - 06:15 PM

Camrelizumab (C) plus rivoceranib (R) vs. sorafenib (S) as first-line therapy for unresectable hepatocellular carcinoma (uHCC): A randomized, phase III trial

Speaker: Dr. Vikas Talreja

06:15 PM - 06:20 PM

Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA

Speaker: Dr. Joydeep Ghosh

06:20 PM - 07:00 PM

PANEL DISCUSSION

Moderator: Dr. T. P. Sahoo

Panelists: Dr. Vineet Govinda Gupta
Dr. Vignesh Kanda Kumar
Dr. Amit Dutt Dwary
Dr. Divyesh Goyal
Dr. Vipul Doshi
Dr. Sameer Srirangwar
Dr. Amit Kumar

PANCREATICOBILIARY CANCERS | Time 7:00 PM to 8:00 PM

07:00 PM - 07:05 PM

Evaluation of gemcitabine and paclitaxel versus gemcitabine alone after FOLFIRINOX failure or intolerance in metastatic pancreatic ductal adenocarcinoma: Results of the randomized phase III PRODIGE 65 - UCGI 36 - GEMPAX UNICANCER study

Speaker: Dr. Chitresh Aggarwal

For the use of a Registered Medical Practitioner, Hospital or Laboratory only.

By accepting this invite to the event, you hereby agree to the T&C at <https://www.drreddys.com/privacy-notice.aspx> in respect of the handling of your personal data by Dr. Reddy's. Your participation at the event shall not be construed to: (a) require you to promote, purchase, prescribe, or otherwise recommend any Company products or services; or (b) interfere with your clinical decision-making.

The opinions expressed in the presentation are solely the views of the speaker.

Click link below for Registration
<https://riverroute.in/gastronomy>

Virtual Meeting Managed by
riverroute
Leaders in Streaming Modules

GASTRONOMY 4.0

Scientific Program

PANCREATICOBILIARY CANCERS | Time 7:00 PM to 8:00 PM

07:05 PM - 07:10 PM	<p>PRODIGE 29-UCGI 26(NEOPAN): A phase III randomised trial comparing chemotherapy with folfirinox or gemcitabine in locally advanced pancreatic carcinoma (LAPC)</p> <p>Speaker: Dr. Akhil Kapoor</p>
07:10 PM - 07:15 PM	<p>Bevacizumab (B) plus FOLFIRI after failure of platinum-etoposide in patients (pts) with advanced neuroendocrine carcinoma (NEC): The PRODIGE 41-BEVANEC randomized phase II study</p> <p>Speaker: Dr. Sushant Mittal</p>
07:15 PM - 07:20 PM	<p>Sequential nab-paclitaxel/gemcitabine followed by modified FOLFOX for first-line metastatic pancreatic cancer: The SEQUENCE trial</p> <p>Speaker: Dr. Shruti Kate</p>
07:20 PM - 08:00 PM	<p>PANEL DISCUSSION</p> <p>Moderator: Dr. Amish Vora</p> <p>Panelists: Dr. Pritam Kataria Dr. Lalit Sharma Dr. Arun Ramanan Dr. S Suresh Dr. Praveen Dr. K Sudheer Reddy Dr. Gunjesh Kumar Singh</p>

For the use of a Registered Medical Practitioner, Hospital or Laboratory only.

By accepting this invite to the event, you hereby agree to the T&C at <https://www.drreddys.com/privacy-notice.aspx> in respect of the handling of your personal data by Dr. Reddy's. Your participation at the event shall not be construed to: (a) require you to promote, purchase, prescribe, or otherwise recommend any Company products or services; or (b) interfere with your clinical decision-making.

The opinions expressed in the presentation are solely the views of the speaker.

GASTRONOMY 4.0

Scientific Program

COLORECTAL CANCERS | Time 8:00 PM to 9:00 PM

08:00 PM - 08:05 PM

Phase III study with FOLFIRI/cetuximab versus FOLFIRI/cetuximab followed by cetuximab (Cet) alone in first-line therapy of RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients: The ERMES study

Speaker: Dr. Niraj Bhatt

08:05 PM - 08:10 PM

FOLFOX/FOLFIRI plus either bevacizumab or panitumumab in patients with initially unresectable colorectal liver metastases (CRLM) and left-sided and RAS/BRAFV600E wild-type tumour: Phase III CAIRO5 study of the Dutch Colorectal Cancer Group

Speaker: Dr. Priya Tiwari

08:10 PM - 08:15 PM

New "PARADIGM" in RAS WT mCRC

Speaker: Dr. Krishna Prasad

08:15 PM - 08:20 PM

Sotorasib in combination with panitumumab in refractory KRAS G12C-mutated colorectal cancer: Safety and efficacy for phase Ib full expansion cohort

Speaker: Dr. Vaibhav Choudhary

08:20 PM - 09:00 PM

PANEL DISCUSSION

Moderator: Dr. Anant Ramaswamy

Panelists: Dr. Lalit Mohan Sharma
Dr. Naresh Somani
Dr. Randeep Singh
Dr. Srinivas Kulkarni
Dr. Murtuza Bohra
Dr. Ghansyam Biswas
Dr. Soumya Surath Panda

For the use of a Registered Medical Practitioner, Hospital or Laboratory only.

By accepting this invite to the event, you hereby agree to the T&C at <https://www.drreddys.com/privacy-notice.aspx> in respect of the handling of your personal data by Dr. Reddy's. Your participation at the event shall not be construed to: (a) require you to promote, purchase, prescribe, or otherwise recommend any Company products or services; or (b) interfere with your clinical decision-making.

The opinions expressed in the presentation are solely the views of the speaker.

Click link below for Registration
<https://riverroute.in/gastronomy>

Virtual Meeting Managed by
riverroute
Leaders in Streaming Modules